Sinha Vikas

CFO Vikas Sinha sold 10,410 SRRK shares at $49.57 (516.1K) amid -100.0% annual revenue decline and -$102.2M net loss.

CFO Vikas Sinha sold 10,410 shares at $49.57, representing 1.7% of his pre-transaction holdings of 630.3K shares. Scholar Rock is deeply unprofitable, posting a -$102.2M net loss with annual revenue declining -100.0%, and currently trades at $47.80—below the $49.57 transaction price and well below the 52-week high of $50.01. At the same ticker, his prior sell on 2026-01-13 was followed by a 90-day return of +16.0%, indicating poorly-timed exit timing. The CFO's 2 prior cross-ticker sells showed similarly unfavorable timing with a 0.00% well-timed rate, suggesting his historical exit decisions have not preceded stock declines.

CFO Vikas Sinha sells 16,755 shares of SRRK at $42.70; stock up 5.0% in 30 days, +66.5% in 90 days.

Vikas Sinha, CFO of Scholar Rock, sold 16,755 shares (16.8K shares) on 2026-01-13 at $42.70, reducing his holdings from 600,000 to 583,245 shares, a -2.8% reduction. The sale occurred while SRRK was trading near its 52-week highs (-0.7% from $46.87), and the stock has appreciated 5.0% over the prior 30 days and 66.5% over the prior 90 days. Sinha's cross-ticker track record shows 1 prior open-market sale with an average 90-day return of +1022.1% after the sale and a well-timed rate of 0.00%, indicating his prior sales were poorly timed relative to subsequent stock performance. Against a backdrop of strong near-term momentum and a historically poor track record for timing sales, this transaction warrants attention as a data point in the context of the company's unprofitable status (net income of $-102.2M most recent full fiscal year) despite robust revenue growth of +76.4% year-over-year.

Director Vikas Sinha sold 160,000 shares of VRNA at $9.39 for $1.5M, reducing stake by 68.2% amid unprofitable operations.

Director Vikas Sinha sold 160,000 shares (160.0K shares) at $9.39 on 2025-05-20, reducing his holding from 234,440 to 74,440 shares—a 68.2% reduction of his pre-transaction position. The sale occurs in the context of an unprofitable company: Verona Pharma reported a net income of $-16.3M over its most recent full fiscal year. The transaction price of $9.39 stands significantly below the current price of $72.69, suggesting the sale occurred during a period when the stock was trading at substantially lower valuations than today. This substantial divestiture by a director, paired with the company's ongoing losses and the historical price differential, warrants investor attention to the company's operational trajectory and the director's remaining conviction level.